Clinical Research Directory

Inclusion Criteria: General: * Participants diagnosed with PD or PPS by a licensed medical professional * Documented diagnosis of PD or PPS ≤ 6 years * Participants with an anticipated survival of at least 3 years in the investigator's opinion * Participants who are willing and able to give informed consent * Participants who can comply with the study protocol over the 6-month duration * Stable medical profile for 60 days prior to the initial intake screening * Participants can ambulate at least 25m without assistance * No known history of heparin-induced thrombocytopenia * Willingness to comply with study requirements and provide informed consent * Participants have no history of adverse reactions to heparin, e.g., HIT, local numbing medications, adhesives, or skin sterilizing agents PD Inclusion Criteria: * Idiopathic Parkinson's disease patients who meet the MDS's Clinical Diagnostic Criteria for Parkinson's disease * Responsive to levodopa or dopamine agonists defined by 33% improvement in "Off"/"On" symptoms by MDS-UPDRS-III * A modified Hoehn and Yahr stage of 3 or less * Neuroimaging findings are consistent with PD and absent of atrophy or other brain pathology inconsistent with PD * "Normal" cognition as assessed by Montreal Cognitive Assessment (MoCA), with a value 26 PPS Inclusion Criteria: (DLB) * High probability of cognitive capacity to give informed consent by the Montreal - Cognitive Assessment (MoCA), with a value 23 * Probable DLB - DLB consortium: Two or more core clinical features are present (including features of parkinsonism for the study), or only one core clinical feature is present, but with one or more indicative biomarkers * Core clinical features: * Fluctuating cognition with pronounced variations in attention and alertness * Recurrent visual hallucinations that are typically well-formed and detailed * Rapid eye movement (REM) sleep behavior disorder (RBD), which may precede cognitive decline * One or more spontaneous cardinal features of parkinsonism: bradykinesia, resting tremor, or rigidity * Indicative biomarkers: * Reduced dopamine transporter uptake in basal ganglia demonstrated by SPECT/PET * Abnormal (low uptake) I-MIBG myocardial scintigraphy * Polysomnographic confirmation of REM sleep without atonia (PSP) * MDS Diagnostic Criteria for probable PSP with predominant parkinsonism (PSP-P) * Ocular motor dysfunction: vertical supranuclear gaze palsy or slow velocity of vertical saccades or frequent macro square wave jerks ("eyelid-opening apraxia") * Ocular motor dysfunction + akinetic-rigid, axial predominant, levodopa resistant or with tremor and/or asymmetric and/or levodopa responsive (akinesia) * "Normal" cognition as assessed by Montreal Cognitive Assessment (MoCA), with a value 26 (MSA) * MDS Diagnostic Criteria for clinically probable MSA * Autonomic dysfunction * Parkinsonism * Cerebellar syndrome, including at least one of gait ataxia, limb ataxia, cerebellar dysarthria, or oculomotor features * "Normal" cognition as assessed by Montreal Cognitive Assessment (MoCA), with a value 26 (CBD) * Chronic progressive course * Asymmetric onset * Higher cortical dysfunction: apraxia, speech apraxia, non-fluent aphasia, alien limb phenomena, or cortical sensory loss * Movement disorder: rigid/akinetic syndrome and either dystonic limb posturing or focal myoclonus in limb, and levodopa-resistant * "Normal" cognition as assessed by Montreal Cognitive Assessment (MoCA), with a value 26 Exclusion Criteria: * Other non-PD/PPS Parkinsonism (e.g., drug-induced, vascular parkinsonism) * No strong familial history of PD/PPS not attributable to environmental exposure or any known genetic predisposition to PD/PPS * Unable to maintain/tolerate supine position with cervical neck extension * Active systemic infection or local infection near the lumbar pelvis region * Any bone marrow aspiration from the pelvis within 6 months of initial screening * Any musculoskeletal-pelvis contraindications to BMA harvest from the PSIS * Concurrent enrollment in another PD/PPS study or having taken/received another investigational intervention within 6 weeks of initial screening * Malignancy diagnosed 2 years prior to initial screening * History of intracranial or nasopharyngeal surgery deemed detrimental to the participant during the trial, including brain surgery/stereotactic procedure for PD/PPS * History of electroconvulsive therapy * Chronic Kidney Disorder (CKD) \> Stage II or eGFR \<60 mL/min * Autoimmune disease, including: * Rheumatoid Arthritis (RA) * Systemic Lupus Erythematosus (SLE) * Any disorders of glucocorticoid excess or diseases requiring systemic steroids or immune-modulating therapies * Cardiac disease deemed significant: * Poorly controlled hypertension (BP 140/90) * NYHA class III or IV congestive heart failure * History of a significant ventricular arrhythmia * Obesity class II or higher (BMI 35) * Moderate-to-uncontrolled diabetes HbA1c 7% * Osteoporosis * A history of other severe systemic disorders, including significant CVA, TBI, seizure, encephalitis, meningitis, or psychiatric disorder that is deemed potentially harmful to the participant by the PI * Positive for HIV, HBV, HCV, or syphilis * Any of the following lab abnormalities: * Hematology: Hgb \< 10 g/dl, ANC \< 1.550/L, platelets \< 100,000 /L * Chemistry: albumin \< 3.0 g/dL, serum creatine \> 1.5 x ULN, total bilirubin \> 1.5 x ULN, AST/ALT/ALP \> 2.0 x ULN * Female or another gender with childbearing potential not willing to adopt barrier method(s) of contraception, plus one other form, including: * Intrauterine system (IUS) * Intrauterine device (IUD) * Oral, injected, or implanted hormonal contraception * Female or another gender who is lactating/breastfeeding or has a positive urine or serum pregnancy test at intake screening * Any disorder that compromises the participant's ability to give appropriate informed consent or hinders the ability to perform the assessment and receive the study's interventions * Any other condition not listed above that is deemed potentially harmful to the participant by the PI